With so many payment and care organization approaches, ACOs are focused on obtaining value for their money spent. Today when an oncologist selects a therapy option for their patient, they rely on clinical trials that study large groups of patients with the same cancer. These trials are considered a success if 20-40% of patients respond to the therapy.
We look forward to meeting you and sharing the latest feedback from clinicians across the country and around the world as they seek better outcomes for their patients by adding Cellworks TRI (Therapy Response Index) to their oncology practice.
At our booth, we invite you to take the TRI Challenge, an intriguing demonstration of our precision medicine based, patient-centric approach to determining an individual patient’s response to alternative drug therapies to help clinicians select the best option first.